The trial will last until the end of April.
"Next, we will make timely recommendations on the COVID-19 treatment according to the results of these clinical trials," Zhang said.
According to him, the researchers scanned more than 70,000 drugs or compounds through computer simulations and in vitro enzyme activity tests, and selected 5,000 potentially effective drug candidates.
Then they were tested at the cellular level against the common coronavirus infection, and about 100 drugs were chosen for further experiments, which helped to select the final drugs for clinical trials, Zhang said.
The most urgent scientific research task is to improve the cure rate and reduce the mortality, which rely on effective clinical treatments, he noted.
New products and technologies have been adopted to treat severe and critically ill patients, a key approach to reduce mortality, and some have achieved good clinical effects, he said.
One of the recent progresses is the development of convalescent plasma. It is processed from the plasma collected from recovered patients, which contains a large amount of protective antibodies.
So far, a total of 11 severe patients from several hospitals in Wuhan have received the convalescent plasma therapy, with all their clinical indicators getting better and no obvious adverse reactions.
Clinical studies on the stem cell therapy, which can inhibit the overreaction of the body's immune system, have also been carried out to treat severe patients, he added.
【国内英语资讯:China Focus: China rallies scientific efforts for effective treatments amid epidemic】相关文章:
★ BBC应大胆创新
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15